Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Osteoporosis Consensus Panel Seeks More Studies To Bone Up On Treatments

This article was originally published in The Gray Sheet

Executive Summary

Further controlled trials are necessary to determine the utility of managing acute vertebral fractures with polymethyl methacrylate (PMMA) bone cement, an independent consensus panel convened by the National Institutes of Health concluded March 29 in Bethesda, Maryland.

You may also be interested in...

Spine Compression Fracture Treatments Compared By Cost, Leak Rate

The potential safety advantages of kyphoplasty over vertebroplasty and its ability to stave off additional spine repair procedures may outweigh its higher cost, according to speakers at the HealthPoint SPINE Summit in New York Oct. 9

Abbott Readying Vildagliptin ER In India Amid Price Competition

Abbott is developing an extended release version of vildagliptin in India, adding a new dimension to the market dynamics for the DPP-4 inhibitor, which has seen a key patent expire. Sustained release vildagliptin products from Wockhardt and Synokem also appear to be in the works.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts